Emerging drugs for adrenocortical carcinoma.
BACKGROUND
Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease.


OBJECTIVE
this paper will review the existing treatment strategies and new perspectives in the management of ACC patients.


CONCLUSIONS
An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.
Berruti
Alfredo
A
Department of Clinical and Biological Science, Oncologia Medica, University of Turin, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy. alfredo.berruti@gmail.com
Ferrero
Anna
A
Sperone
Paola
P
Daffara
Fulvia
F
Reimondo
Giuseppe
G
Papotti
Mauro
M
Dogliotti
Luigi
L
Angeli
Alberto
A
Terzolo
Massimo
M